ActionA startup focused on real-world evidence in healthcare announced a five-year research collaboration with the FDA’s Oncology Center of Excellence (OCE).
OCE will use Aetion’s Evidence platform to discover and analyze sources of real-world data that can be used to research cancer prevention, clinical care, diagnosis and treatment.
The collaboration will assess real-world endpoints, measure health disparities, and evaluate causal inference methods. This research will continue till 2027.
“We are proud to partner with the FDA’s Oncology Center of Excellence to advance the use of real-world evidence and conduct important research to help better serve vulnerable and underrepresented populations,” Carolyn Magill, CEO of Aetien, said in a statement. Proud to partner with.” “Our collaboration advances our mission to better understand which treatments work for which patients and brings us closer to achieving health equality among cancer patients.”
Since its inception in 2013, the New York-based health tech company has received multiple investments.
In 2021, Aetion scored $110 million in Series C funding, bringing the company’s total raised to $212 million. The funding round comes less than a year after the company closed its $19 million Series B extension round.
In 2019, Sanofi has merged its real-world data platform with Aetion’s Evidence platform. Sanofi’s real-world data platform, DARWIN, provides de-identified patient data, which Aetion’s Evidence platform will analyze for insights on drug effectiveness, safety and value.
During the peak of the pandemic in 2020, Aetion partners with healthcare data platform HealthVerity will launch tools to help biopharma companies and regulators find COVID-19 treatments.
In December, Aetion announced the FDA The Office of Data Analytics and Research extended its contract, initially signed in 2020, to 2023 to examine real-world data about COVID-19 medical countermeasures. Aetion will expand its work to evaluate data standardization in the context of COVID-19.